Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel

The Pharmacogenomics Journal volume 14, pages 248–255 (2014)Cite this article

Subjects

Abstract

The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a phase II trial. This study evaluated weekly docetaxel, as first-line treatment for metastatic breast cancer. Existing data from in vitro and animal model experiments suggest that docetaxel at low doses has anti-angiogenic activity. DNA was extracted from blood samples of 86 patients participating in the trial. Genotyping was performed for selected single-nucleotide polymorphisms (SNPs; VEGF−2578, −1498, −1154, and +936). Moreover, due to the highly polymorphic nature of the studied areas, we were able to analyze additional registered SNPs. All candidate genotypes were evaluated for associations with overall survival (OS), progression-free survival (PFS) and response rate. The VEGF−1154 GG genotype was more frequent in patients not responding to treatment compared with responders (42.9% vs 0.0%, P=0.048). Moreover, the VEGF−2578 AA genotype was associated with longer PFS compared with CC (hazard ratio (HR)=0.40; 95% confidence interval (CI) 0.17–0.98; pairwise P=0.0457). Patients with the VEGF−1190 GG genotype demonstrated shorter PFS compared with those with the alternative genotypes (GA and AA) combined (HR=3.85; 95% CI: 1.20–12.50; P=0.0224). In addition, the VEGF−2551/−2534 homozygous del18bp and VEGF−2430/−2425 homozygous ins1bp genotypes were associated with worse PFS compared with no deletion and no insertion, respectively (HR=2.49; 95% CI: 1.02–6.07; pairwise P=0.0442 and HR=2.57; 95% CI: 1.05–6.27; pairwise P=0.0385, respectively). Furthermore, patients with the VEGF−1498 CC genotype exhibited longer median OS compared with those with the alternatives genotypes (CT and TT) combined (HR=0.27; 95% CI: 0.08–0.89; P=0.0311). In multivariate analysis, the VEGF−2578 AA genotype retained its significance (P=0.0220) for PFS. Our results support the association of specific VEGF genotypes with clinical outcome in patients with metastatic breast cancer treated with a potentially anti-angiogenic regimen, such as weekly docetaxel. However, current results should be validated prospectively in larger cohorts.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1996; 1: 27–31.

    Google Scholar 

  2. Ferrara N . VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795–803.

    Google Scholar 

  3. Hicklin DJ, Ellis LM . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011–1027.

    Google Scholar 

  4. Shibuya M, Claesson-Welsh L . Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549–560.

    Google Scholar 

  5. Kerbel RS . Tumor angiogenesis. N Engl J Med 2008; 358: 2039–2049.

    Google Scholar 

  6. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112: 1455–1461.

    Google Scholar 

  7. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663–1671.

    Google Scholar 

  8. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007; 67: 281–288.

    Google Scholar 

  9. Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N . Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 2009; 124: 2989–2996.

    Google Scholar 

  10. Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A et al. Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. Oncol Rep 2012; 27: 216–224 doi: 10.3892/or.2011.1504.

    Google Scholar 

  11. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672–4678.

    Google Scholar 

  12. Simon RM, Paik S, Hayes DF . Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446–1452.

    Google Scholar 

  13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM . REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006; 100: 229–235.

    Google Scholar 

  14. Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 2009; 8: 2496–2508.

    Google Scholar 

  15. Schneider BP, Radovich M, Miller KD . The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009; 15: 5297–5302.

    Google Scholar 

  16. Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J 2012; 12: 468–475 doi: 10.1038/tpj.2011.37.

    Google Scholar 

  17. Mohammadi M, Ollier W . Hutchinson IV. A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells. Hum Immunol 2003; 64: S125.

    Google Scholar 

  18. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 2006; 8: R22.

    Google Scholar 

  19. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005; 11: 3647–3653.

    Google Scholar 

  20. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65: 5015–5019.

    Google Scholar 

  21. Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T et al. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep 2007; 18: 1155–1163.

    Google Scholar 

  22. Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14: 7871–7877.

    Google Scholar 

  23. Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). San Antonio Breast Cancer Symposium 2011, Abstract S4–S8.

  24. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013; 108: 1052–1060.

    Google Scholar 

  25. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L et al. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 2013; 19: 1281–1289.

    Google Scholar 

  26. Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA . Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 2006; 96: 209–215.

    Google Scholar 

  27. Coltelli L, Allegrini G, Orlandi P, Giuntini N, Alì G, Fioravanti A et al. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics 2009; 10: 1225–1229.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece

    A K Koutras & H P Kalofonos

  2. Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

    V Kotoula & K Papadopoulou

  3. Department of Clinical Therapeutics, ‘Alexandra’ Hospital, University of Athens School of Medicine, Athens, Greece

    C Papadimitriou & F Zagouri

  4. Department of Medical Oncology, ‘Papageorgiou’ Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

    D Dionysopoulos & G Fountzilas

  5. Department of Pathology, University Hospital of Patras, Patras, Greece

    H P Kourea

  6. Second Department of Medical Oncology, ‘Metropolitan’ Hospital, Piraeus, Greece

    D V Skarlos

  7. Third Department of Medical Oncology, ‘Agii Anargiri’ Cancer Hospital, Athens, Greece

    E Samantas

  8. Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece

    P Kosmidis

  9. Second Department of Internal Medicine, Oncology Section, ‘Hippokration’ Hospital, Athens, Greece

    D Pectasides

Authors
  1. A K Koutras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Kotoula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Papadimitriou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Dionysopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Zagouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H P Kalofonos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H P Kourea
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D V Skarlos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Samantas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Papadopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Kosmidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D Pectasides
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G Fountzilas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A K Koutras.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koutras, A., Kotoula, V., Papadimitriou, C. et al. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel. Pharmacogenomics J 14, 248–255 (2014). https://doi.org/10.1038/tpj.2013.36

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2013.36

Keywords

Search

Advanced search

Quick links